Cargando…
Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial
This is a phase Ib study of anlotinib plus a programmed death-ligand 1 (PD-L1) inhibitor TQB2450 for platinum-resistant or -refractory ovarian cancer. Thirty-four patients are enrolled and receive treatment. The objective response rate (ORR) is 47.1%, and the disease control rate is 97.1%. The media...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381412/ https://www.ncbi.nlm.nih.gov/pubmed/35858589 http://dx.doi.org/10.1016/j.xcrm.2022.100689 |
_version_ | 1784769073535516672 |
---|---|
author | Lan, Chun-Yan Zhao, Jing Yang, Fan Xiong, Ying Li, Rong Huang, Yu Wang, Jing Liu, Chang Bi, Xue-Han Jin, Hai-Hong Meng, Jin Zhao, Wei-Hong Zhang, Li Wang, Ya-Fei Zheng, Min Huang, Xin |
author_facet | Lan, Chun-Yan Zhao, Jing Yang, Fan Xiong, Ying Li, Rong Huang, Yu Wang, Jing Liu, Chang Bi, Xue-Han Jin, Hai-Hong Meng, Jin Zhao, Wei-Hong Zhang, Li Wang, Ya-Fei Zheng, Min Huang, Xin |
author_sort | Lan, Chun-Yan |
collection | PubMed |
description | This is a phase Ib study of anlotinib plus a programmed death-ligand 1 (PD-L1) inhibitor TQB2450 for platinum-resistant or -refractory ovarian cancer. Thirty-four patients are enrolled and receive treatment. The objective response rate (ORR) is 47.1%, and the disease control rate is 97.1%. The median duration of response (DOR) has not been reached, and 61.3% of patients have a DOR of at least 8 months. The median progression-free survival (PFS) is 7.8 months, and the median overall survival (OS) has not been reached. The PD-L1-positive group has an ORR of 25.0%, whereas the PD-L1-negative group has an ORR of 92.9%. Treatment-related grade 3 or 4 adverse events (AEs) occur in 70.6% of patients, with the most common being hypertension (29.4%) and palmar-plantar erythrodysesthesia syndrome (29.4%). Anlotinib plus TQB2450 show promising antitumor activity and manageable toxicities in patients with platinum-resistant or -refractory ovarian cancer. A phase 3 randomized controlled trial to further validate our findings is ongoing. |
format | Online Article Text |
id | pubmed-9381412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-93814122022-08-18 Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial Lan, Chun-Yan Zhao, Jing Yang, Fan Xiong, Ying Li, Rong Huang, Yu Wang, Jing Liu, Chang Bi, Xue-Han Jin, Hai-Hong Meng, Jin Zhao, Wei-Hong Zhang, Li Wang, Ya-Fei Zheng, Min Huang, Xin Cell Rep Med Article This is a phase Ib study of anlotinib plus a programmed death-ligand 1 (PD-L1) inhibitor TQB2450 for platinum-resistant or -refractory ovarian cancer. Thirty-four patients are enrolled and receive treatment. The objective response rate (ORR) is 47.1%, and the disease control rate is 97.1%. The median duration of response (DOR) has not been reached, and 61.3% of patients have a DOR of at least 8 months. The median progression-free survival (PFS) is 7.8 months, and the median overall survival (OS) has not been reached. The PD-L1-positive group has an ORR of 25.0%, whereas the PD-L1-negative group has an ORR of 92.9%. Treatment-related grade 3 or 4 adverse events (AEs) occur in 70.6% of patients, with the most common being hypertension (29.4%) and palmar-plantar erythrodysesthesia syndrome (29.4%). Anlotinib plus TQB2450 show promising antitumor activity and manageable toxicities in patients with platinum-resistant or -refractory ovarian cancer. A phase 3 randomized controlled trial to further validate our findings is ongoing. Elsevier 2022-07-19 /pmc/articles/PMC9381412/ /pubmed/35858589 http://dx.doi.org/10.1016/j.xcrm.2022.100689 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Lan, Chun-Yan Zhao, Jing Yang, Fan Xiong, Ying Li, Rong Huang, Yu Wang, Jing Liu, Chang Bi, Xue-Han Jin, Hai-Hong Meng, Jin Zhao, Wei-Hong Zhang, Li Wang, Ya-Fei Zheng, Min Huang, Xin Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial |
title | Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial |
title_full | Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial |
title_fullStr | Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial |
title_full_unstemmed | Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial |
title_short | Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial |
title_sort | anlotinib combined with tqb2450 in patients with platinum-resistant or -refractory ovarian cancer: a multi-center, single-arm, phase 1b trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381412/ https://www.ncbi.nlm.nih.gov/pubmed/35858589 http://dx.doi.org/10.1016/j.xcrm.2022.100689 |
work_keys_str_mv | AT lanchunyan anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT zhaojing anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT yangfan anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT xiongying anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT lirong anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT huangyu anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT wangjing anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT liuchang anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT bixuehan anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT jinhaihong anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT mengjin anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT zhaoweihong anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT zhangli anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT wangyafei anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT zhengmin anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial AT huangxin anlotinibcombinedwithtqb2450inpatientswithplatinumresistantorrefractoryovariancanceramulticentersinglearmphase1btrial |